Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ERN1 | O75460 | 5/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477951 | 0.85 | PRKDC (0.43) | CA1CA2PRKDCALDH1A1L3MBTL1 | |
| SCHEMBL129781 | 0.82 | CA2 (0.48) | CA1CA2PRKDCALDH1A1L3MBTL1 | |
| SCHEMBL31538163 | 0.81 | CA1 (0.47) | CA1CA2ALDH1A1L3MBTL1ERN1 | |
| SCHEMBL4018313 | 0.79 | ALDH1A1 (0.47) | CA1CA2PRKDCALDH1A1L3MBTL1 | |
| SCHEMBL29162635 | 0.79 | DRD1 (0.35) | PRKDCLMNA | |
| SCHEMBL3840934 | 0.78 | MCL1 (0.47) | CA1CA2ALDH1A1L3MBTL1ERN1 | |
| SCHEMBL22123331 | 0.78 | CA1 (0.58) | CA1CA2ALDH1A1ERN1TRIM24 | |
| SCHEMBL22231418 | 0.78 | ERN1 (0.54) | CA1CA2PRKDCERN1TRIM24 | |
| SCHEMBL4595685 | 0.78 | CA1 (0.44) | CA1CA2ALDH1A1L3MBTL1ERN1 | |
| SCHEMBL29729025 | 0.77 | CA1 (0.59) | CA1CA2PRKDCALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| US-12624050-B2 | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| EP-3805231-B1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-113227101-B | Salt or crystal form containing tricyclic derivative and pharmaceutical composition thereof | 上海翰森生物医药科技有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-114835729-B | Inhibitor containing tricyclic derivatives, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-112830935-B | Crystal form containing tricyclic derivative free alkali and pharmaceutical composition thereof | 上海翰森生物医药科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230014383-A1 | THREE FUSED RING DERIVATIVE-CONTAINING SALT OR CRYSTAL FORM AND PHARMACEUTICAL COMPOSITION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20230014383-A1 | THREE FUSED RING DERIVATIVE-CONTAINING SALT OR CRYSTAL FORM AND PHARMACEUTICAL COMPOSITION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| EP-4100381-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-12-14 | — | — | EP | disclosed |
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-18 | — | — | US | disclosed |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| WO-2016128456-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-18 | — | — | WO | disclosed |
| EP-3055309-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | Takeda Pharmaceutical Company Limited (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-9353108-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-31 | — | — | US | disclosed |
| US-9120777-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-01 | — | — | US | disclosed |
| WO-2015064083-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | WO | disclosed |
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-30 | — | — | US | disclosed |
| WO-2015052910-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | WO | disclosed |
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | CA1 3181/4885CA2 1009/4885PRKDC 4805/4885 |
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR4, SSTR2 | CA1 1724/4885CA2 684/4885PRKDC 3322/4885 |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | SSTR5, SSTR4, SSTR2 | CA1 1690/4885CA2 656/4885PRKDC 3355/4885 |
| US-20230014383-A1 | THREE FUSED RING DERIVATIVE-CONTAINING SALT OR CRYSTAL FORM AND PHARMACEUTICAL COMPOSITION THEREOF | AKT2, AKT3, PIK3R5 | CA1 2422/4885CA2 1818/4885PRKDC 519/4885 |
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR4, SSTR2 | CA1 1665/4885CA2 656/4885PRKDC 3257/4885 |
| US-12624050-B2 | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof | OGDH, ME1, GCDH | CA1 10/4885CA2 33/4885PRKDC 990/4885 |
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | PIK3CA, PIK3R1, PIK3CD | CA1 1020/4885CA2 339/4885PRKDC 183/4885 |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | CA1 4026/4885CA2 4674/4885PRKDC 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.